NCT04260256View on ClinicalTrials.gov

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit
Interventions
DRUG

[18F]F-AraG

\[18F\]F AraG injection and PET Scan Two tumor biopsies of single lesion

Trial Locations (2)

94305

RECRUITING

Stanford University, Stanford

97239

RECRUITING

Oregon Health and Science University, Portland

Sponsors
All Listed Sponsors
collaborator

Stanford University

OTHER

collaborator

Oregon Health and Science University

OTHER

lead

CellSight Technologies, Inc.

INDUSTRY

NCT04260256 - A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter